微波消融治疗T1a期小肾肿块:扩展至3厘米以上
回顾性分析126例接受微波消融的小肾癌患者,比较<3 cm与3-4 cm肿瘤的肿瘤学和肾功能结局。两组36个月累积局部无复发生存率分别为94.6%与91.4%,肿瘤大小不是局部无复发生存率的显著预后因素,肾功能无显著变化。作者认为微波消融对选择性3-4 cm肾肿块是有前景的治疗策略,现有AUA指南推荐热消融用于<3 cm肿瘤,可能需重新审视以将T1a期肿瘤纳入微波消融,不论大小。
要点
- 3-4 cm组总复发6/64(9.4%),其中局部4/6、无局部进展的转移2/6;<3 cm组总复发2/62(3.2%),均为局部复发。
- 36个月累积局部无复发生存率<3 cm组94.6% vs 3-4 cm组91.4%,肿瘤大小不是局部无复发生存率的显著预后因素。
- 微波消融前后肾功能无显著变化,患者合并症与RENAL肾肿瘤评分显著影响慢性肾病分期变化。
核心结论
- 微波消融在3-4 cm与<3 cm肾肿瘤中肿瘤学结局、并发症率和肾功能保留相当,作者认为对选择性患者是有前景的治疗策略,并提示现行AUA指南(推荐热消融用于<3 cm肿瘤)可能需重新审视以纳入T1a期肿瘤行微波消融,不论大小。
研究设计与样本
- 回顾性分析一个前瞻性维护的数据库,纳入接受微波消融的<3 cm或3-4 cm肾癌患者共126例;术后约6个月及此后每年进行影像学随访;微波消融前后计算血清肌酐和估算肾小球滤过率(eGFR);采用Kaplan-Meier法估计局部无复发生存率(LRFS),Cox比例风险回归评估肿瘤大小作为预后因素,线性和有序logistic回归建模eGFR变化与慢性肾病(CKD)分期的预测因素。
诊断标准与关键数值
- 总复发:<3 cm组2/62(3.2%)vs 3-4 cm组6/64(9.4%);<3 cm组2例均为局部复发,3-4 cm组6例中4例为局部、2例为无局部进展的转移;36个月累积局部无复发生存率<3 cm组94.6% vs 3-4 cm组91.4%;肿瘤大小不是局部无复发生存率的显著预后因素;微波消融前后肾功能无显著变化;患者合并症和RENAL肾肿瘤评分显著影响CKD分期变化。
临床应用与阅片要点
- 作者认为微波消融对3-4 cm肾肿块在选择性患者中是有前景的治疗策略,并提示现行AUA指南推荐热消融用于<3 cm肿瘤,可能需重新审视以将T1a期肿瘤纳入微波消融,不论大小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the oncological and renal function outcomes for patients receiving microwave ablation (MWA) in tumors < 3 and 3-4 cm.
METHODS: Retrospective analysis of a prospectively maintained database identified patients with < 3 or 3-4 cm renal cancers undergoing MWA. Radiographic follow-up occurred at approximately 6 months post-procedure and annually thereafter. Serum creatinine and estimated glomerular filtration rate (eGFR) were calculated before and 6-months post-MWA. Local recurrence-free survival (LRFS) was estimated using the Kaplan-Meier method. Tumor size was evaluated as a prognostic factor using Cox proportional-hazards regression. Predictors for change in eGFR and chronic kidney disease (CKD) stage were modeled using linear and ordinal logistic regression.
RESULTS: A total of 126 patients fit the inclusion criteria. Overall recurrences were 2/62 (3.2%) and 6/64 (9.4%) for < 3 versus 3-4 cm. Both recurrences in the < 3 cm group were local, 4/6 in the 3-4 cm group were local and 2/6 were metastatic without local progression. For < 3 versus 3-4 cm, cumulative LRFS at 36 months was 94.6% versus 91.4%. Tumor size was not a significant prognostic factor for LRFS. Renal function did not change significantly after MWA. Patient comorbidities and RENAL nephrometry score significantly affected change in CKD.
CONCLUSION: With comparable oncological outcomes, complication rates, and renal function preservation, MWA is a promising management strategy for renal masses of 3-4 cm in select patients. Our findings suggest that current AUA guidelines, which recommend thermal ablation for tumors < 3 cm, may need review to include T1a tumors for MWA, regardless of size.
引用
- Qiu, Ballantyne, Yeaman, et al. Microwave ablation of the T1a small renal mass: expanding beyond 3 cm. Abdom Radiol (NY). 2023. PMID: 37212853. doi:10.1007/s00261-023-03935-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。